SCHEDULE: RA Capital Boosts Solid Biosciences Stake to 9.9%

RA Capital Management and its affiliates increased their beneficial ownership in Solid Biosciences Inc. to 9.9% through recent open market purchases totaling over $23.7 million.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") have filed an Amendment No. 12 to their Schedule 13D.
• The Reporting Persons collectively beneficially own 9,313,756 shares of Solid Biosciences Inc. common stock, representing 9.9% of the class.
• This ownership includes 8,828,224 shares directly held by RA Capital Healthcare Fund, L.P., 109,661 shares by RA Capital Nexus Fund, L.P., 28,569 shares by a separately managed account, and pre-funded warrants exercisable for up to 8,178,412 shares.
• The pre-funded warrants include a beneficial ownership blocker, preventing exercise if it would result in ownership exceeding 9.99% of outstanding common stock, currently limiting exercise to 9,313,756 shares.
• Between March 11, 2026, and March 17, 2026, RA Capital Healthcare Fund, L.P. purchased a total of 3,155,031 shares of common stock through open market transactions.
• The aggregate purchase price for these shares was $23,710,116.85, funded by the Fund's working capital.
• The purchases occurred at weighted-average prices ranging from $7.28 to $7.79 per share.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. A significant increase in stake by a sophisticated institutional investor like RA Capital, particularly through open market purchases, suggests high conviction in Solid Biosciences' long-term value and prospects.

Positives

• A significant institutional investor, RA Capital, has increased its stake in Solid Biosciences, indicating confidence in the company's future prospects.
• The substantial investment of over $23.7 million in open market purchases demonstrates a strong commitment from RA Capital.
• The continued accumulation of shares by a prominent healthcare-focused fund suggests a positive long-term view of Solid Biosciences' value.

Risks

• The beneficial ownership blocker on pre-funded warrants limits RA Capital's immediate ability to increase its stake beyond 9.99% without further disclosures or changes in the blocker terms.
• The value of RA Capital's investment is subject to market fluctuations of Solid Biosciences' common stock.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Solid Biosciences Inc. It primarily details the current beneficial ownership and recent acquisition activities of RA Capital Management and its affiliates.

Industry Context

StockSavvy.ai notes that increased institutional ownership, especially from a specialized healthcare fund like RA Capital, can signal confidence in a biotechnology company's pipeline, strategic direction, or valuation. This move by RA Capital suggests they see significant upside potential in Solid Biosciences, a company focused on Duchenne muscular dystrophy, potentially anticipating positive clinical developments or market re-rating within the competitive gene therapy and rare disease space.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence and attracting further investment.
• Company Management: A significant stake by an active investor like RA Capital could lead to increased engagement or influence on strategic decisions.

Key Dates

Recommendation

The substantial increase in beneficial ownership by RA Capital Management, a highly respected healthcare-focused institutional investor, through significant open market purchases, signals strong conviction in Solid Biosciences' valuation and future potential. This aggressive accumulation of shares suggests that a seasoned investor sees compelling value, making it a 'buy' recommendation for other investors.

Keywords

Solid Biosciences, RA Capital Management, Schedule 13D, Beneficial Ownership, Common Stock, Institutional Investment, Healthcare Fund, Biotechnology, Equity Stake, Open Market Purchases